ClinicalTrials.gg

Program

CM512

A development code. Also written as “CM512 injection”.

Its studies are mostly in Rhinosinusitis · Dermatitis, Atopic · Rhinitis, Allergic, Perennial · Chronic Urticaria · Asthma, led by Keymed Biosciences.

Furthest: phase 3, since Sep 2, 202610 company-led studies, 8 open or runningNext primary completion: Jul 21, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keymed Biosciences108 open or runningphase 3since Sep 2, 2026Aug 11, 2024Jul 21, 2027phase 2 · NCT07011524

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2024First study: phase 1 study in Dermatitis, AtopicFirst studyNCT06553209 · 110 enrolled · China
  2. Apr 9, 20252 phase 2 studiesNCT06930612, NCT06947980
  3. May 12, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06980142 · 204 planned
  4. Jun 5, 2025Phase 2 study in AsthmaNCT07011524 · 200 planned · China
  5. Sep 3, 2025Phase 2 study in Chronic UrticariaNCT07166211 · 48 planned · China
  6. Nov 13, 2025Phase 2 study in Dermatitis, AtopicNCT07230483 · 246 planned · China
  7. Apr 2, 2026Phase 2 study in Chronic Rhinosinusitis With Nasal PolyposisNCT07519577 · 120 planned · China
  8. Sep 2, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)Phase 3 reachedNCT07807826 · 240 planned · China
  9. Oct 16, 2026Phase 2 study in Rhinitis, Allergic, PerennialNCT07890350 · 200 planned · China

Ahead

  1. Nov 2, 2026Primary completion: phase 2 study in Chronic UrticariaNCT07166211
  2. Jul 21, 2027Primary completion: phase 2 study in AsthmaNCT07011524
  3. Nov 2027Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)NCT07807826
  4. Dec 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07230483

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07890350Rhinitis, Allergic, Perennial · China2Not yet recruitingJun 2028200
NCT07807826Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) · China3Not yet recruitingNov 2027240
NCT07519577Chronic Rhinosinusitis With Nasal Polyposis · China2Not yet recruitingMay 31, 2028120
NCT07230483Dermatitis, Atopic · China2RecruitingDec 2027246
NCT07166211Chronic Urticaria · China2RecruitingNov 2, 202648
NCT07011524Asthma · China2RecruitingJul 21, 2027200
NCT06980142Pulmonary Disease, Chronic Obstructive2Not yet recruitingMar 17, 2028204
NCT06947980Dermatitis, Atopic · China2RecruitingJul 18, 2026200
NCT06930612Chronic Rhinosinusitis With Nasal Polyposis · China2CompletedApr 20, 2026120
NCT06553209Dermatitis, Atopic · China1CompletedAug 26, 2025110

How it is read

Names in the registry

  • “CM512”, 8 entries
  • “CM512 injection”, 2 entries

Codes read as this program: CM512.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.